Published in Vaccine Weekly, May 14th, 2003
Mojave Therapeutics, Inc. is developing heat shock protein-based immunotherapies. Brian Barber, PhD, its chief scientific officer and senior vice-president, delivered a talk entitled "Delivering T-cell immunity with heat shock proteins."
In a previously reported study of 27 metastatic melanoma patients (AJCC Stages III and IV), formulations based on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.